Seattle Genetics (SGEN) will receive undisclosed milestone payments from Genentech after the...


Seattle Genetics (SGEN) will receive undisclosed milestone payments from Genentech after the Roche unit advanced into Phase II trials two antibody-drug conjugates (ADC) that use SGEN's technology. The studies will evaluate the performance of the ADCs with Rituxan, which Genentech markets, in treating non-Hodgkin lymphoma and B-cell lymphoma. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs